The chart is not accessible to screen readers. Please switch to the table view to access the data.
Advertisement
Advertisement
Sales share of Amgen three major drugs from 2020 to 2025
Amgen three major drugs 2020-2025, by sales share
In 2025, Prolia, Enbrel, and Otezla were the best-selling products of Amgen. The decline in sales share was mainly due to competitive displacement and pricing pressure from other pharmaceutical companies. Amgen is a U.S.-based multinational biopharmaceutical company, headquartered in Thousand Oaks, California.Â
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Other statistics that may interest you Amgen
Company positioning
6
- Premium Statistic Leading global biotech companies 2024, by number of employees
- Premium Statistic Major 50 pharmaceutical companies - Rx sales and R&D spending 2024
- Premium Statistic Total worldwide prescription drug revenue - projection 2018-2032
- Basic Statistic Percentage of global pharmaceutical sales by technology 2016-2030
- Basic Statistic Sales per employee of select U.S. biotech and drug companies Q3-Q4 2025
- Basic Statistic AI readiness of big pharma companies 2025
Financial scale & structure
5
Research and development
3
Competitive landscape
5
- Basic Statistic Revenue share of Roche's Pharmaceuticals division by therapy area 2013-2025
- Premium Statistic AbbVie's revenue by therapy area 2022-2025
- Premium Statistic Sanofi revenue by segment 2014-2025
- Premium Statistic Gilead Sciences revenue 2006-2024
- Basic Statistic Regeneron Pharmaceuticals revenue 2021-2025
Further Content: You might find this interesting as well
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Amgen, & U.S. Securities and Exchange Commission. (February 14, 2026). Sales share of Amgen three major drugs from 2020 to 2025 [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 24, 2026, from /statistics/1660305/amgen-major-three-drug-sales-share/
Amgen, und U.S. Securities and Exchange Commission. "Sales share of Amgen three major drugs from 2020 to 2025." Chart. February 14, 2026. ÌÇÐÄÆƽâ°æ. Accessed July 24, 2026. /statistics/1660305/amgen-major-three-drug-sales-share/
Amgen, U.S. Securities and Exchange Commission. (2026). Sales share of Amgen three major drugs from 2020 to 2025. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 24, 2026. /statistics/1660305/amgen-major-three-drug-sales-share/
Amgen, and U.S. Securities and Exchange Commission. "Sales Share of Amgen Three Major Drugs from 2020 to 2025." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 14 Feb 2026, /statistics/1660305/amgen-major-three-drug-sales-share/
Amgen & U.S. Securities and Exchange Commission, Sales share of Amgen three major drugs from 2020 to 2025 ÌÇÐÄÆƽâ°æ, /statistics/1660305/amgen-major-three-drug-sales-share/ (last visited July 24, 2026)
Sales share of Amgen three major drugs from 2020 to 2025 [Graph], Amgen, & U.S. Securities and Exchange Commission, February 14, 2026. [Online]. Available: /statistics/1660305/amgen-major-three-drug-sales-share/
Advertisement